Intercell AG

euro adhoc: Intercell AG
Joint Ventures/Cooperation/Collaboration
Vaccine formulated with Intercell's adjuvant IC31® part of a broader collaboration to fight Tuberculosis

@@start.t1@@--------------------------------------------------------------------------------   Disclosure announcement transmitted by euro adhoc. The issuer is responsible   for the content of this announcement. --------------------------------------------------------------------------------@@end@@

Research & Development


» TB-vaccine collaboration between Sanofi Pasteur and Statens Serum Institut    (SSI) including Intercell´s adjuvant IC31® » World-leading Tuberculosis research and vaccine development aiming to make    a new TB vaccine widely available in shortest possible time

Intercell AG today announced that a Tuberculosis vaccine, which is currently tested in clinical trials and which contains antigens discovered by Statens Serum Institut formulated with Intercell's innovative adjuvant IC31®, will be further developed in a partnership between SSI and Sanofi Pasteur.

SSI and Intercell will continue their world-leading collaboration in the field of Tuberculosis research and vaccine development with Intercell´s proprietary adjuvant IC31®, and by the involvement of Sanofi Pasteur extend the activities into more advanced phases aiming to make a new TB vaccine widely available in shortest possible time.

The collaboration with Aeras Global TB Vaccine Foundation in the TB vaccine field will continue and together the parties represent the extensive range of technology and expertise necessary to solve this complex global health problem.

"We are very happy that Sanofi Pasteur is now contributing all its outstanding vaccine expertise to this very promising tuberculosis vaccine program" comments Intercell's Chief Executive Officer Gerd Zettlmeissl. "The preclinical and the Phase I clinical studies performed so far have impressively proven that our novel adjuvant IC31® will play an important role in this combined vaccine approach."

Financial details are not disclosed.

About Tuberculosis (TB) TB causes the death of more than 1.5 million people every year and one-third of the world´s population is infected by the bacteria "Mycobacterium tuberculosis" which makes this disease one of the most severe global health problems. The existing Bacillus Calmette-Guérin vaccine (BCG) vaccine is a live vaccine that, when given to newborns, provides good protection against TB for 10-15 years. However, when the protective effect decreases, yet another BCG vaccination does not provide sufficient TB protection. Therefore, a new type of TB vaccine is needed to address the need of TB protection in the adult population.

About IC31® Vaccines, based on antigens alone, are not sufficient to maximize protection. Adjuvants are needed to educate the immune system to recognize and eliminate the pathogens efficiently. IC31® is an adjuvant that induces T-cell and B-cell responses by using a unique synthetic formulation which combines the immunostimulating properties of an anti-microbial peptide, KLK, and an immunostimulatory oligodeoxynucleotide, ODN1a. The two component solution can be simply mixed with antigens; no conjugation is required. Intercell currently uses IC31® in collaborations with a number of global vaccine companies and biotech companies.

@@start.t2@@end of announcement                                                 euro adhoc

ots Originaltext: Intercell AG
Im Internet recherchierbar:

Further inquiry note:
Intercell AG
Dr. Werner Lanthaler
Chief Financial Officer
+43 1 20620-120

Branche: Biotechnology
ISIN:      AT0000612601
WKN:        A0D8HW
Börsen:  Wiener Börse AG / official market

Weitere Meldungen: Intercell AG

Das könnte Sie auch interessieren: